首页> 外文期刊>The International journal of drug policy >‘Beyond the willing & the waiting’ — The role of peer-based approaches in hepatitis C diagnosis & treatment
【24h】

‘Beyond the willing & the waiting’ — The role of peer-based approaches in hepatitis C diagnosis & treatment

机译:'超越愿意& 等待' - 基于同伴的方法在丙型肝炎诊断&amp中的作用; 治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract This commentary seeks to examine the role, value and importance of peer-based programmatic approaches for ensuring the effective roll-out of the new hepatitis C (HCV) treatments among those most affected — that is, people who inject drugs (PWID). The authors examine recent approaches to HCV treatment in Australia including the provision of universal access to the new DAA regimens regardless of acquisition, genotype or severity of disease. These approaches are contextualised within wider global strategies to support HCV elimination as a public health threat by 2030 (WHO, 2016). Despite the unprecedented opportunity presented by the availability of the new treatments, the fact remains that those most affected by hepatitis C are still largely hidden and disconnected from the health system and are likely to stay that way without targeted education and support. There is a need to for greater investment in new and innovative HCV+ PWID peer education approaches for HCV diagnosis and treatment that add value to existing models of care to improve pathways and support people across their entire treatment journey. Key components include expanding existing peer-based programmes and developing new innovative peer initiatives, supporting the development of the PWID peer workforce, developing new, targeted peer education resources and promoting linkages and partnerships between peer based and HCV treatment service providers in primary and community settings. Our approach to HCV elimination needs to take account of people’s broader lives, their vulnerabilities, their life journeys and their potential points of connection, engagement and access. Peer-based organisations and networks provide that unique point of engagement and access for those HCV+ PWID for whom the health system is an unfamiliar even forbidding place or for whom hepatitis C can be but one of many overwhelming issues in the lives.
机译:摘要此评论旨在审查基于同伴的方案方法的角色,价值和重要性,以确保在受影响最严重的新丙型肝炎(HCV)治疗中的有效推出 - 即注射药物(PWID)的人。作者审查了最近在澳大利亚的HCV治疗方法,包括提供对新DAA方案的普遍获得,无论收购,基因型或疾病严重程度。这些方法在更广泛的全球战略中,以支持HCV消除2030年的公共卫生威胁(2016年)。尽管新疗法的可用性提供了前所未有的机会,但该事实仍然是丙型肝炎受影响最大的人仍然很大程度上隐藏和断开了卫生系统,并且可能在没有针对性教育和支持的情况下保持这种方式。需要为新的和创新性HCV + PWID同伴教育方法进行更大的投资,用于HCV诊断和治疗方法,为现有的护理模型增加价值,以改善整个治疗之旅的途径和支持人员。关键组成部分包括扩大现有的基于同行的方案并开发新的创新同行计划,支持PWID同行劳动力的发展,开发新的,有针对性的同伴教育资源以及在主要和社区设置中促进同行和HCV治疗服务提供商之间的联系和伙伴关系。我们对HCV消除的方法需要考虑人们更广泛的生命,他们的漏洞,他们的生活旅程及其潜在的联系点,参与和访问。基于同行的组织和网络提供了卫生系统甚至难以禁止的那些HCV + PWID的独特的参与点和访问,甚至是丙型肝炎,而是人们中的许多压倒性问题之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号